Transmitted antiretroviral drug resistance among acute and recent HIV infections in North Carolina from 1998 to 2007.
BACKGROUND
Transmitted drug resistance (TDR) limits antiretroviral options and thus complicates the management of HIV-positive patients. HIV disproportionately affects the southern US, but available national estimates of TDR prevalence principally reflect large metropolitan centres outside this region.


METHODS
The Duke/UNC Acute HIV Program has collected data on acute or recent HIV infections (ARHI) in North Carolina since 1998. Acute infections represent antibody-negative, RNA-positive patients. Recent infection was determined by history of HIV testing or concordance between detuned ELISA and antibody avidity assays. Genotypic sequence data from the earliest collected pretreatment plasma samples were analysed with the Stanford HIV Database and screened for surveillance drug resistance mutations (SDRMs).


RESULTS
A total of 253 individuals with ARHI between May 1998 and May 2007 had complete genotypic sequence data for analysis; 39.5% were acute infections, 78.7% were male, 64.8% were non-White and 53.8% were men who have sex with men. The overall prevalence of TDR was 17.8%, with SDRMs for non-nucleoside/nucleotide reverse transcriptase inhibitors (NNRTIs) in 9.5% of the cohort. Mutations for nucleoside/nucleotide reverse transcriptase inhibitors (NRTIs) were detected in 7.5% and for protease inhibitors (PIs) in 3.2%. K103N was the most common mutation (7.5%). Thymidine analogue mutations were found in 4.7% of samples; the most common PI SDRM was L90M (2.4%). Dual- or triple-class antiretroviral resistance was rare, encountered in only six (2.4%) samples.


CONCLUSIONS
The prevalence of TDR in North Carolina is similar to estimates from the US metropolitan areas. These findings have implications for initial regimen selection and secondary prevention efforts outside of large, metropolitan HIV epicentres.
Hurt
Christopher B
CB
Division of Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. christopher_hurt@med.unc.edu
McCoy
Sandra I
SI
Kuruc
Joann
J
Nelson
Julie Ae
JA
Kerkau
Melissa
M
Fiscus
Susan
S
McGee
Kara
K
Sebastian
Joseph
J
Leone
Peter
P
Pilcher
Christopher
C
Hicks
Charles
C
Eron
Joseph
J
D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D000368:Aged; D019380:Anti-HIV Agents / Q000494:pharmacology* / Q000627:therapeutic use; D024882:Drug Resistance, Viral / Q000235:genetics; D005260:Female; D015658:HIV Infections / Q000188:drug therapy / Q000635:transmission* / Q000821:virology; D017320:HIV Protease Inhibitors / Q000494:pharmacology / Q000627:therapeutic use; D015497:HIV-1 / Q000187:drug effects* / Q000235:genetics; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D009657:North Carolina / Q000453:epidemiology; D021141:Nucleic Acid Amplification Techniques; D011159:Population Surveillance / Q000379:methods; D015995:Prevalence; D018894:Reverse Transcriptase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D055815:Young Adult
D019380:Anti-HIV Agents; D017320:HIV Protease Inhibitors; D018894:Reverse Transcriptase Inhibitors
Int J STD AIDS. 2008 May;19(5):297-304
18482958
N Engl J Med. 1999 Dec 16;341(25):1865-73
10601505
N Engl J Med. 2002 Aug 8;347(6):385-94
12167680
JAMA. 2002 Jul 10;288(2):181-8
12095382
BMJ. 2005 Dec 10;331(7529):1368
16299012
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Aug 5;822(1-2):201-8
16005269
J Acquir Immune Defic Syndr. 2008 Oct 1;49(2):196-204
18769348
J Urban Health. 2001 Sep;78(3):419-32
11564846
AIDS. 2007 Jan 11;21(2):215-23
17197813
J Acquir Immune Defic Syndr. 2003 Feb 1;32(2):215-22
12571533
J Infect Dis. 2005 Sep 15;192(6):958-66
16107947
J Pharm Biomed Anal. 2007 Mar 12;43(4):1562-7
17236737
Proc Natl Acad Sci U S A. 2001 Nov 20;98(24):13907-12
11698656
BMJ. 2001 May 5;322(7294):1087-8
11337435
AIDS. 2007 May 11;21(8):1035-9
17457098
JAMA. 2002 Jul 10;288(2):216-21
12095386
Am J Health Behav. 2003 Jul-Aug;27(4):373-9
12882431
Natl Vital Stat Rep. 2008 Apr 24;56(10):1-120
18512336
Am J Public Health. 2004 Oct;94(10):1695-703
15451735
N Engl J Med. 2005 May 5;352(18):1873-83
15872202
AIDS. 2001 May 4;15(7):837-45
11399956
Sex Transm Dis. 2006 Jul;33(7 Suppl):S32-8
16794553
J Chromatogr B Analyt Technol Biomed Life Sci. 2003 Jul 5;791(1-2):137-47
12798174
AIDS. 2004 Jan 23;18(2):227-35
15075540
Top HIV Med. 2007 Aug-Sep;15(4):119-25
17720996
J Infect Dis. 2004 Jun 15;189(12):2174-80
15181563
Am J Public Health. 2004 Oct;94(10):1682-6
15451731
Nucleic Acids Res. 2003 Jan 1;31(1):298-303
12520007
N Engl J Med. 2008 May 15;358(20):2095-106
18480202